← Back to Search

Digital Mammography for Breast Cancer

Phase 4

Waitlist Available

Led By Basak Dogan, MD

Research Sponsored by University of Texas Southwestern Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 4 years

Awards & highlights

Study Summary

This trial will help researchers learn if CEDM is better than mammography at predicting early neoadjuvant therapy response and pathologic complete response (pCR) in patients with invasive breast cancer.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 4 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 4 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Correlation of Residual Tumor Size With Pathologic Size

Diagnostic Accuracy of Contrast-enhanced Mammography in Assessing pCR or Non Response

Sensitivity of Predicting pCR (Pathologic Complete Response) for CEDM

+3 more

Secondary outcome measures

To identify any patient preference differences between CEDM and breast MRI

Trial Design

1Treatment groups

Experimental Treatment

Group I: Breast cancer patientsExperimental Treatment2 Interventions

Patients with ipsilateral intact biopsy-proven breast cancer

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of Texas Southwestern Medical CenterLead Sponsor

1,047 Previous Clinical Trials

1,053,793 Total Patients Enrolled

21 Trials studying Breast Cancer

6,256 Patients Enrolled for Breast Cancer

Basak Dogan, MDPrincipal InvestigatorUT Southwestern Medical Center

2 Previous Clinical Trials

41 Total Patients Enrolled

2 Trials studying Breast Cancer

41 Patients Enrolled for Breast Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what disorder is Digital Mammography most commonly applied?

"Typically, Digital Mammography is used to battle communicable illnesses. In addition, it can be employed for antisepsis, the prevention of infection in minor wounds or burns, and treating existing infections in such injuries."

Answered by AI

Is Digital Mammography a novel approach in the realm of clinical trials?

"Currently, 15 research initiatives examining Digital Mammography are underway; two of which are in Phase 3. Numerous medical centres across Sevilla, Vizcaya have initiated clinical trials for this imaging technique and 37 locations altogether carry out these studies."

Answered by AI

Has Digital Mammography received confirmation from the FDA?

"Digital Mammography's safety has been adequately established which is reflected in its score of 3. This treatment has already gone through the fourth phase of clinical trials, granting it approval for use."

Answered by AI

Are there any vacancies for participants in this research trial?

"At present, this trial is not enrolling patients. The first post was made on January 22nd 2020 and the information was last updated November 9th 2021. If you are seeking other studies related to breast cancer, 1403 clinical trials currently have open recruitment and 15 of those involve Digital Mammography specifically."

Answered by AI

What is the current enrollment rate of individuals participating in this clinical trial?

"At present, this trial is not accepting new patients. The study was posted on January 22nd 2020 and the last edit occurred November 9th 2021. For those searching for other studies, 1403 trials related to breast cancer are currently recruiting participants along with 15 trials surrounding digital mammography that require volunteers."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Performance of Contrast-Enhanced Spectral Mammography to Assess Neoadjuvant Chemotherapy Response (CEDM)

Basak Dogan, MD 2020. "Performance of Contrast-Enhanced Spectral Mammography to Assess Neoadjuvant Chemotherapy Response (CEDM)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04625517.